← 返回

冷冻保存对 CAR-T 生产与临床反应的影响

英文原题:Impact of cryopreservation on CAR T production and clinical response.

查看英文原题

Impact of cryopreservation on CAR T production and clinical response.

PubMed 2022/10/06(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过继性细胞治疗中的嵌合抗原受体(CAR)T细胞已成为血液系统恶性肿瘤患者的有效治疗选择。FDA批准的CAR-T 产品在集中式设施中由新鲜或冷冻的白细胞单采物制备,冷冻保存的CAR-T 输注产品被运送回患者。越来越多的临床中心在本地生产CAR-T 细胞,这使得可以使用新鲜和冷冻保存的PBMCs和CAR-T 细胞。

在此,我们在118例接受新鲜CAR-T 细胞治疗的患者队列中,以及在数例患者中进行头对头比较,确定了冷冻保存对PBMCs和CD19 CAR-T 细胞的影响。从白细胞单采产品中获得冷冻保存的PBMCs,其红细胞和T细胞较少,但足以生产用于治疗的CAR-T 细胞。PBMCs的回收率与转导效率、生产过程结束时获得的CAR-T 细胞数量、体外反应性或对CAR-T 治疗的缓解率之间没有相关性。

我们能够证明,在生产过程中冷冻保存、储存并在较晚时间点恢复扩增的CAR-T 细胞,可产生足够的细胞数量用于治疗,并导致完全缓解。包括T细胞亚型、趋化因子受体和共抑制/共刺激分子在内的表型分析显示,与冷冻对应物相比,新鲜CAR-T 细胞显著表达更多TIM-3,并含有较少的效应T细胞。

此外,新鲜CAR-T 输注产品表现出增强的体外抗肿瘤反应性,然而冷冻保存的CAR-T 细胞仍显示出高抗肿瘤效力和特异性。冷冻保存的CAR-T 细胞的回收率在缓解和未缓解患者中相似。尽管新鲜CAR-T 输注产物表现出更高的抗肿瘤反应性,但使用冻存PBMCs作为起始材料和冻存CAR-T 输注产物似乎是可行的选择,因为冻存产物仍表现出高的体外效力,且冷冻保存似乎不影响临床结局。

展开英文摘要原文

Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has become an efficient treatment option for patients with hematological malignancies. FDA approved CAR T products are manufactured in centralized facilities from fresh or frozen leukapheresis and the cryopreserved CAR T infusion product is shipped back to the patient. An increasing number of clinical centers produce CAR T cells on-site, which enables the use of fresh and cryopreserved PBMCs and CAR T cells.

Here we determined the effect of cryopreservation on PBMCs and CD19 CAR T cells in a cohort of 118 patients treated with fresh CAR T cells and in several patients head-to-head. Cryopreserved PBMCs, obtained from leukapheresis products, contained less erythrocytes and T cells, but were sufficient to produce CAR T cells for therapy. There was no correlation between the recovery of PBMCs and the transduction efficacy, the number of CAR T cells obtained by the end of the manufacturing process, the in vitro reactivity, or the response rate to CAR T therapy.

We could show that CAR T cells cryopreserved during the manufacturing process, stored and resumed expansion at a later time point, yielded sufficient cell numbers for treatment and led to complete remissions. Phenotype analysis including T cell subtypes, chemokine receptor and co-inhibitory/stimulatory molecules, revealed that fresh CAR T cells expressed significantly more TIM-3 and contained less effector T cells in comparison to their frozen counterparts.

In addition, fresh CAR T infusion products demonstrated increased in vitro anti-tumor reactivity, however cryopreserved CAR T cells still showed high anti-tumor potency and specificity. The recovery of cryopreserved CAR T cells was similar in responding and non-responding patients.

Although fresh CAR T infusion products exhibit higher anti-tumor reactivity, the use of frozen PBMCs as staring material and frozen CAR T infusion products seems a viable option, as frozen products still exhibit high in vitro potency and cryopreservation did not seem to affect the clinical outcome.

论文信息

作者
Brezinger-Dayan K、Itzhaki O、Melnichenko J、Kubi A、Zeltzer LA、Jacoby E、Avigdor A、Shapira Frommer R
单位
Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Ramat Gan, Israel.Israel
期刊
Frontiers in oncology2022
原文标识
PubMed 36276077 · DOI 10.3389/fonc.2022.1024362